Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 30 for:    ( Map: Albania )

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03426254
Recruitment Status : Active, not recruiting
First Posted : February 8, 2018
Last Update Posted : April 2, 2019
Sponsor:
Collaborator:
BioGene Pharmaceutical
Information provided by (Responsible Party):
Center Trials & Treatment

Brief Summary:
To assess the safety and efficacy of two forms of Talazoparib therapy (injections subcutaneously Talazoparib and oral form for the treatment in the equivalent therapeutics dose

Condition or disease Intervention/treatment Phase
Advanced or Recurrent Solid Tumors Breast Neoplasm Biological: Injections Subcutaneously Talazoparib Drug: Oral capsules Talazoparib Phase 1

Detailed Description:
The intent of this study was to assess the safety and efficacy of two forms of Talazoparib therapy for the treatment of advanced solid tumors . After an enrollment period, patients will randomized to receive oral Talazoparib (1 mg, one times a day ) or subcutaneously Talazoparib (1 mg by subcutaneous injection with NovoPen / Autopen) one times a day in the appropriate volume

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The intent of this study was to assess the safety and efficacy of two forms of Talazoparib therapy for the treatment of advanced solid tumors . After an enrollment period, patients will randomized to receive oral Talazoparib (1 mg, one times a day ) or subcutaneously Talazoparib (1 mg subcutaneous injection by pen-syringe / mechanical dispenser) .
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Advanced Solid Tumors ( Phase I )
Actual Study Start Date : February 8, 2018
Estimated Primary Completion Date : March 20, 2020
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Injections Subcutaneously Talazoparib

Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Auto-Injector delivers a single dose of 1 mg Talazoparib injection (subcutaneous)

Biological: Injections Subcutaneously Talazoparib
Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28
Other Names:
  • MDV3800
  • BMN673

Active Comparator: Oral capsules Talazoparib
Patients receive 1 mg of Talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Oral capsules Talazoparib
Patients receive 1 mg of Talazoparib PO QD on days 1-28.
Other Names:
  • MDV3800
  • BMN673




Primary Outcome Measures :
  1. Frequency of occurrence and evaluation of adverse events in the use of Subcutaneously Talazoparib ( 1 mg / dose ) [ Time Frame: Anticipated in about 12 month following first patient enrolled ]

    Frequency of occurrence and evaluation of adverse events in the use of Subcutaneously Talazoparib , assessed by percentage of patients with any Adverse Event (AE), leading to Study Drug Discontinuation, Serious Adverse Event (SAE), related to study drug, SAE related to study drug.

    Incidence of toxicity, graded according to the National Cancer Institute (NCI) CTCAE version 4.03 Incidence of toxicity, graded according to the National Cancer Institute (NCI) CTCAE version 4.03



Secondary Outcome Measures :
  1. Clinical Benefit of Injections Subcutaneously Talazoparib [ Time Frame: Every 9 weeks for 12 months ]
    Clinical benefit (CB) defined as any of the following, complete response, partial response, or stable disease for > 24 weeks by RECIST 1.1. Assessments performed using computed tomography (CT) or magnetic resonance imaging (MRI) or ultrasound examination (Use) scan every 9 weeks.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed and dated informed consent form (by the patient or a legally acceptable representative as per the local regulations) obtained prior to initiation of any study-specific procedure and treatment.
  • Female of at least 21 years of age.
  • Histologically or cytologically confirmed advanced solid tumor with no available standard approved treatment options in the opinion of the Investigator
  • Eastern Cooperative Oncology Group (ECOG) Performance status (PS) ≤ 2.
  • Renal function at screening and enrollment as defined by the
  • Patient has had no clinically significant change in renal status within 3 months prior to screening, according to Investigator's review of clinical patient records.
  • Patient is not currently on hemodialysis and/or peritoneal dialysis for management of chronic kidney disease or acute failure/conditions.
  • Patient has no unstable renal function, defined as a change in estimated glomerular filtration rate (eGFR) (calculated with the MDRD equation) of > 25% for patients with mild and moderate renal impaired or as a change in eGFR > 30% for patients with severe renal impaired, from screening to enrollment.
  • Received at least 1 and no more than 3 platinum-based chemotherapy regimens (prior bevacizumab is allowed) and the last dose is ≥ 28 days before randomization
  • No prior PARP inhibitor treatment
  • Adequate other organ function at screening and enrollment.
  • Female patients of childbearing potential must have a negative serum pregnancy test at screening, and must agree to use a highly effective birth control method from the time of the first dose of study drug through 60 days after the last dose of study drug.
  • Female patients must not be breastfeeding at screening nor during the study participation until 60 days after the last dose of study drug.
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.

Exclusion Criteria:

  • Terminology Criteria for Adverse Events [CTCAE] grade ≤ 1) from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.
  • Use of any investigational agent within 14 days before randomization.
  • Had > 2 paracentesis procedures within 28 days before randomization.
  • Major surgery within 14 days before randomization.
  • Requirement for intravenous alimentation (at the time of randomization).
  • Seropositive for human immunodeficiency virus (HIV).
  • Any serious or unstable medical condition that interferes with ability to tolerate treatment or assessments associated with the protocol.
  • Gastrointestinal disorder affecting absorption.
  • Known or suspected hypersensitivity to any of the talazoparib capsule components.
  • Any condition or reason that interferes with ability to participate in the study, tolerate treatment or assessments associated with the protocol, causes undue risk, or complicates the interpretation of safety data, in the opinion of the Investigator or Medical Monitor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03426254


Locations
Layout table for location information
Albania
University -Mother Theresa- Hospital, Oncology Dep.
Tirana, Albania, 1
Switzerland
BioGene Pharmaceutical
Zürich, ZH, Switzerland, 8091
Sponsors and Collaborators
Center Trials & Treatment
BioGene Pharmaceutical

Layout table for additonal information
Responsible Party: Center Trials & Treatment
ClinicalTrials.gov Identifier: NCT03426254     History of Changes
Other Study ID Numbers: TST-9-H
First Posted: February 8, 2018    Key Record Dates
Last Update Posted: April 2, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Center Trials & Treatment:
Subcutaneously Talazoparib
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents